Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.22
DEPO's Cash to Debt is ranked lower than
79% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. DEPO: 0.22 )
Ranked among companies with meaningful Cash to Debt only.
DEPO' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 15.19 Max: No Debt
Current: 0.22
Equity to Asset 0.25
DEPO's Equity to Asset is ranked lower than
91% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. DEPO: 0.25 )
Ranked among companies with meaningful Equity to Asset only.
DEPO' s Equity to Asset Range Over the Past 10 Years
Min: -2.63  Med: 0.38 Max: 0.97
Current: 0.25
-2.63
0.97
Interest Coverage 2.36
DEPO's Interest Coverage is ranked lower than
90% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 123.58 vs. DEPO: 2.36 )
Ranked among companies with meaningful Interest Coverage only.
DEPO' s Interest Coverage Range Over the Past 10 Years
Min: 1.73  Med: 270.73 Max: 9999.99
Current: 2.36
1.73
9999.99
F-Score: 4
Z-Score: 1.32
M-Score: 0.62
WACC vs ROIC
23.75%
16.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 31.44
DEPO's Operating margin (%) is ranked higher than
93% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. DEPO: 31.44 )
Ranked among companies with meaningful Operating margin (%) only.
DEPO' s Operating margin (%) Range Over the Past 10 Years
Min: -601.86  Med: -14.47 Max: 72.49
Current: 31.44
-601.86
72.49
Net-margin (%) 11.63
DEPO's Net-margin (%) is ranked higher than
69% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. DEPO: 11.63 )
Ranked among companies with meaningful Net-margin (%) only.
DEPO' s Net-margin (%) Range Over the Past 10 Years
Min: -555.44  Med: -13.99 Max: 75.05
Current: 11.63
-555.44
75.05
ROE (%) 14.79
DEPO's ROE (%) is ranked higher than
72% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. DEPO: 14.79 )
Ranked among companies with meaningful ROE (%) only.
DEPO' s ROE (%) Range Over the Past 10 Years
Min: -333.8  Med: 20.07 Max: 532.43
Current: 14.79
-333.8
532.43
ROA (%) 5.12
DEPO's ROA (%) is ranked higher than
57% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. DEPO: 5.12 )
Ranked among companies with meaningful ROA (%) only.
DEPO' s ROA (%) Range Over the Past 10 Years
Min: -66.64  Med: -6.53 Max: 73.87
Current: 5.12
-66.64
73.87
ROC (Joel Greenblatt) (%) 123.38
DEPO's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. DEPO: 123.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DEPO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2282.52  Med: -260.35 Max: 8060.52
Current: 123.38
-2282.52
8060.52
Revenue Growth (3Y)(%) 35.50
DEPO's Revenue Growth (3Y)(%) is ranked higher than
92% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. DEPO: 35.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DEPO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.7  Med: 25.55 Max: 420.5
Current: 35.5
-69.7
420.5
EBITDA Growth (3Y)(%) 43.20
DEPO's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. DEPO: 43.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
DEPO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.8  Med: 6.85 Max: 84.2
Current: 43.2
-55.8
84.2
EPS Growth (3Y)(%) 16.40
DEPO's EPS Growth (3Y)(%) is ranked higher than
64% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. DEPO: 16.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
DEPO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.8  Med: -6.30 Max: 180.8
Current: 16.4
-58.8
180.8
» DEPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

DEPO Guru Trades in Q1 2015

Joel Greenblatt 1,414,563 sh (+16.11%)
Paul Tudor Jones 42,414 sh (+0.12%)
Steven Cohen Sold Out
» More
Q2 2015

DEPO Guru Trades in Q2 2015

Paul Tudor Jones 26,100 sh (-38.46%)
Joel Greenblatt 842,188 sh (-40.46%)
» More
Q3 2015

DEPO Guru Trades in Q3 2015

Jim Simons 104,146 sh (New)
Paul Tudor Jones 40,800 sh (+56.32%)
Joel Greenblatt 264,236 sh (-68.63%)
» More
Q4 2015

DEPO Guru Trades in Q4 2015

John Hussman 200,000 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about DepoMed Inc

Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma
Steven Mandel’s hedge fund, Lone Pine Capital, on July 27 initiated a position in Horizon Pharma Plc (NASDAQ:HZNP), according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 23.60
DEPO's P/E(ttm) is ranked lower than
71% of the 804 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.70 vs. DEPO: 23.60 )
Ranked among companies with meaningful P/E(ttm) only.
DEPO' s P/E(ttm) Range Over the Past 10 Years
Min: 2.32  Med: 9.43 Max: 123.38
Current: 23.6
2.32
123.38
Forward P/E 9.07
DEPO's Forward P/E is ranked higher than
87% of the 409 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.38 vs. DEPO: 9.07 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.50
DEPO's PE(NRI) is ranked lower than
64% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.60 vs. DEPO: 25.50 )
Ranked among companies with meaningful PE(NRI) only.
DEPO' s PE(NRI) Range Over the Past 10 Years
Min: 2.34  Med: 9.43 Max: 123.38
Current: 25.5
2.34
123.38
P/B 2.84
DEPO's P/B is ranked lower than
62% of the 934 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.21 vs. DEPO: 2.84 )
Ranked among companies with meaningful P/B only.
DEPO' s P/B Range Over the Past 10 Years
Min: 2  Med: 4.42 Max: 48.18
Current: 2.84
2
48.18
P/S 2.37
DEPO's P/S is ranked higher than
50% of the 934 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.42 vs. DEPO: 2.37 )
Ranked among companies with meaningful P/S only.
DEPO' s P/S Range Over the Past 10 Years
Min: 1.38  Med: 3.55 Max: 530
Current: 2.37
1.38
530
PFCF 11.01
DEPO's PFCF is ranked higher than
86% of the 481 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.29 vs. DEPO: 11.01 )
Ranked among companies with meaningful PFCF only.
DEPO' s PFCF Range Over the Past 10 Years
Min: 2.33  Med: 9.76 Max: 276.5
Current: 11.01
2.33
276.5
POCF 10.86
DEPO's POCF is ranked higher than
78% of the 653 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.33 vs. DEPO: 10.86 )
Ranked among companies with meaningful POCF only.
DEPO' s POCF Range Over the Past 10 Years
Min: 2.26  Med: 9.59 Max: 251.36
Current: 10.86
2.26
251.36
EV-to-EBIT 11.59
DEPO's EV-to-EBIT is ranked higher than
74% of the 824 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.49 vs. DEPO: 11.59 )
Ranked among companies with meaningful EV-to-EBIT only.
DEPO' s EV-to-EBIT Range Over the Past 10 Years
Min: -302.2  Med: -2.80 Max: 102.9
Current: 11.59
-302.2
102.9
EV-to-EBITDA 7.97
DEPO's EV-to-EBITDA is ranked higher than
82% of the 862 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.85 vs. DEPO: 7.97 )
Ranked among companies with meaningful EV-to-EBITDA only.
DEPO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -582.9  Med: -2.30 Max: 124.5
Current: 7.97
-582.9
124.5
Shiller P/E 81.19
DEPO's Shiller P/E is ranked lower than
80% of the 177 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.68 vs. DEPO: 81.19 )
Ranked among companies with meaningful Shiller P/E only.
DEPO' s Shiller P/E Range Over the Past 10 Years
Min: 84.17  Med: 123.71 Max: 387.25
Current: 81.19
84.17
387.25
Current Ratio 1.68
DEPO's Current Ratio is ranked lower than
63% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. DEPO: 1.68 )
Ranked among companies with meaningful Current Ratio only.
DEPO' s Current Ratio Range Over the Past 10 Years
Min: 0.57  Med: 3.23 Max: 56
Current: 1.68
0.57
56
Quick Ratio 1.62
DEPO's Quick Ratio is ranked higher than
50% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. DEPO: 1.62 )
Ranked among companies with meaningful Quick Ratio only.
DEPO' s Quick Ratio Range Over the Past 10 Years
Min: 0.57  Med: 3.01 Max: 56
Current: 1.62
0.57
56
Days Inventory 63.97
DEPO's Days Inventory is ranked higher than
79% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. DEPO: 63.97 )
Ranked among companies with meaningful Days Inventory only.
DEPO' s Days Inventory Range Over the Past 10 Years
Min: 93.22  Med: 226.72 Max: 613.73
Current: 63.97
93.22
613.73
Days Sales Outstanding 58.55
DEPO's Days Sales Outstanding is ranked higher than
65% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. DEPO: 58.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
DEPO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.13  Med: 29.91 Max: 347.08
Current: 58.55
12.13
347.08
Days Payable 23.27
DEPO's Days Payable is ranked lower than
91% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. DEPO: 23.27 )
Ranked among companies with meaningful Days Payable only.
DEPO' s Days Payable Range Over the Past 10 Years
Min: 30.8  Med: 150.89 Max: 1113.92
Current: 23.27
30.8
1113.92

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.51
DEPO's Price/Projected FCF is ranked lower than
58% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.19 vs. DEPO: 2.51 )
Ranked among companies with meaningful Price/Projected FCF only.
DEPO' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.18  Med: 3.40 Max: 335
Current: 2.51
1.18
335
Price/Median PS Value 0.71
DEPO's Price/Median PS Value is ranked higher than
83% of the 928 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.11 vs. DEPO: 0.71 )
Ranked among companies with meaningful Price/Median PS Value only.
DEPO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.42  Med: 3.13 Max: 123.5
Current: 0.71
0.42
123.5
Earnings Yield (Greenblatt) (%) 8.60
DEPO's Earnings Yield (Greenblatt) (%) is ranked higher than
83% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. DEPO: 8.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DEPO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1  Med: 16.30 Max: 266.4
Current: 8.6
1
266.4

More Statistics

Revenue(Mil) $426
EPS $ 0.68
Beta1.67
Short Percentage of Float20.84%
52-Week Range $13.27 - 33.74
Shares Outstanding(Mil)60.48

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 340 497 600 696
EPS($) 0.80 1.85 1.77 2.24
EPS without NRI($) 0.80 1.85 1.77 2.24

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DPO.Germany,
DepoMed Inc was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. The Products that comprise its specialty pharmaceutical business are Gralise, Zipsor (diclofenac potassium) liquid filled capsules, its non-steriodal anti-inflammatory drug for the treatment of mild to moderate acute pain, CAMBIA, its non-steriodal anti-inflammatory drug for the acute treatment of migraine attacks, and Lazanda nasal spray, its product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The Company's operation and business are subject to a number of other laws and regulations, including those relating to the workplace, privacy, laboratory practices and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances as well as controlled substances.
» More Articles for DEPO

Headlines

Articles On GuruFocus.com
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
UBS Starts Depomed At Buy, Says Nucynta Has More Potential Than Market Thinks Feb 09 2016
Depomed Announces Favorable Markman Ruling in Nucynta® and Nucynta® ER Patent Litigation Feb 08 2016
Coverage initiated on DepoMed by Piper Jaffray Feb 08 2016
Depomed to Present at Healthcare Conferences in February Feb 03 2016
Depomed Announces Save the Date for 2016 Analyst and Investor Day Jan 27 2016
Depomed Announces Save the Date for 2016 Analyst and Investor Day Jan 27 2016
Depomed, Inc.: Price momentum supported by strong fundamentals Jan 21 2016
DEPOMED INC Files SEC form 8-K, Other Events Jan 19 2016
Depomed Announces Closing of Acquisition of U.S. Rights to Cebranopadol From Grunenthal Jan 04 2016
Depomed Announces Closing of Acquisition of U.S. Rights to Cebranopadol From Grunenthal Jan 04 2016
Depomed, Inc. breached its 50 day moving average in a Bearish Manner : December 29, 2015 Dec 29 2015
Depomed, Inc. breached its 50 day moving average in a Bearish Manner : December 14, 2015 Dec 14 2015
Depomed, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 11 2015
[$$] Horizon Pharma to Buy Crealta for $510 Million Dec 11 2015
Direction of Market Influences - Research on Depomed, Novavax, Boyd Gaming and Owens-Illinois Dec 09 2015
DEPOMED INC Financials Dec 08 2015
DEPO: Depomed Enhances its Pain Management Franchise by Acquiring Cebranopadol Dec 04 2015
Depomed, Inc. breached its 50 day moving average in a Bearish Manner : December 4, 2015 Dec 04 2015
Horizon Drops DepoMed Acquisition: Helps IBB Mid-Cap Performance Nov 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK